KRAS and endometrioid adenocarcinoma: For instance, although PI3K and KRAS mutations frequently occur in AH/EIN and endometrioid carcinoma [6], they do not lead to protein expression changes, making them unsuitable as immunohistochemical markers; (3) Availability of commercial antibodies—for practical application, preferred markers should have commercially available antibodies.